Bloomberg News

Brainsway Gets FDA Approval for Multi-Center Bipolar Trial

November 02, 2011

Nov. 1 (Bloomberg) -- Brainsway Ltd. said it received approval from the U.S. Food and Drug Administration to begin a multi-center trial to test the efficacy of its Deep TMS device for the treatment of bipolar disorder, according to a filing today with the Tel Aviv Stock Exchange.

To contact the reporter on this story: Shoshanna Solomon in Tel Aviv at ssolomon22@bloomberg.net

To contact the editor responsible for this story: Alisa Odenheimer at aodenheimer@bloomberg.net


Cash Is for Losers
LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus